Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.
Audrey Abella, 02 Jul 2020
The highly selective SGLT2 inhibitor bexagliflozin demonstrated significant efficacy and safety in controlling hyperglycaemia, weight, and blood pressure (BP) in patients with type 2 diabetes (T2D) who were at high risk of cardiovascular (CV) events, results of the BEST** trial have shown.
18 Jul 2019
In the treatment of patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC), de-escalating dose and volume of radiotherapy (RT) or chemoradiotherapy (CRT) based on response to induction chemotherapy appears to positively affect oncologic outcomes and reduce toxicity, according to data from the phase II OPTIMA trial.

Metformin prevents prednisone-induced hyperglycaemia in haematological cancers

04 Jun 2020

Use of metformin is effective in preventing hyperglycaemia in nondiabetic cancer patients exposed to high-dose prednisone-based chemotherapy, results of a randomized study have shown.

Twenty-four nonhyperglycaemia haematological cancer patients on current or newly initiated high-dose prednisone-based chemotherapy were included in this prospective, randomized controlled trial conducted at the Kenyatta National Hospital Oncology Clinic and Wards in Nairobi, Kenya.

Patients were randomly assigned to receive metformin 850 mg once then 850 mg twice daily for two successive weeks each or standard care (control group). They were subjected to once weekly fasting and 2-hour postprandial glucose measurements for 4 weeks.

Only 18 patients completed the study (seven treatment and 11 control). Among control patients, 72.7 percent (95 percent confidence interval [CI], 45.5–90.9) developed prediabetes using fasting glucose and 54.5 percent (95 percent CI, 27.3–81.8) using 2-hour postprandial glucose. One patient (14.3 percent, 95 percent CI, 0–42.9) in the treatment group developed prediabetes using fasting glucose. No prediabetes was found using the 2-hour postprandial glucose.

No significant between-group difference was seen in the analysis of mean fasting glucose, but significant differences were noted in mean 2-hour postprandial glucose in week 2 (p=0.0144), week 3 (p=0.0095), and week 4 (p=0.0074) of the study.

Of note, double-dose metformin (1,700 mg) appeared to be more effective than single dose (850 mg; fasting: p=1.0000; 2-hour postprandial: p=0.4531) in lowering blood glucose.

“Research has established the development of steroid-induced hyperglycaemia as a glucometabolic side effect of high-dose prednisone therapy,” the investigators said. “Few studies, however, have demonstrated preventative measures that could effectively curtail this side effect in susceptible patients undergoing high-dose prednisone treatment.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.
Audrey Abella, 02 Jul 2020
The highly selective SGLT2 inhibitor bexagliflozin demonstrated significant efficacy and safety in controlling hyperglycaemia, weight, and blood pressure (BP) in patients with type 2 diabetes (T2D) who were at high risk of cardiovascular (CV) events, results of the BEST** trial have shown.
18 Jul 2019
In the treatment of patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC), de-escalating dose and volume of radiotherapy (RT) or chemoradiotherapy (CRT) based on response to induction chemotherapy appears to positively affect oncologic outcomes and reduce toxicity, according to data from the phase II OPTIMA trial.